US biotech company Generex has announced that the Canadian Intellectual Property Office has granted its patent titled "Pharmaceutical Compositions for Buccal and Pulmonary Application." Generex develops formulations for buccal delivery using its RapidMist metered dose device, which is essentially an MDI designed to deliver aerosol to the oral cavity instead of to the lungs. Read the company’s press release.
Generex gets Canadian patent for delivery system
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA